• Mashup Score: 0
    ASCO 2025 Top 10 Abstracts - 7 hour(s) ago

    Explore the ASCO 2025 top 10 abstracts and stay updated on the latest breakthroughs in cancer research and treatments.

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      🚨 ASCO 2025 Top 10 Abstracts Countdown! 🚨 🔟 #VERIFY: Ruxolitinib for polycythemia vera 9⃣ #NIVOPOSTOP: Nivolumab + chemo for head/neck cancer 8⃣ #NIAGARA: ctDNA + durvalumab for bladder cancer ARTICLE HERE: https://t.co/fjTT9zfYF7 7⃣ #CheckMate816: Nivolumab + chemo for NSCLC https://t.co/4KlwxfvVYe

  • Mashup Score: 3
    2026 NCI Drops from $7.22B to $4.10B: Cancer Research Budget Cuts - 1 day(s) ago

    Learn about the major shifts in the 2026 cancer research budget. What does this mean for cancer funding in the coming years?

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      💰 The 2026 NCI budget drops from $7.22B to $4.10B—a 43% cut 📉. How will this impact the future of cancer research? 🧠 Has your research been impacted? ARTICLE: https://t.co/8vECcOPmVs YOUTUBE: https://t.co/2S7nzR4YNQ @OncoAlert @ASCO @marklewismd @StephenVLiu @mtmdphd https://t.co/SgW2LBsZvc

  • Mashup Score: 8
    RAS Inhibitor Resistance in PDAC: Insights from AACR 2025 - 18 day(s) ago

    Explore the challenges of RAS inhibitor resistance in PDAC. Learn how KRAS mutations affect treatment outcomes.

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      KRAS drives 95% of PDAC, Survival is 10% at 5 years. 🩺 🌟Resistance to RAS inhibitors involves EGFR/HER2 mutations 🌟PTEN loss, MET amplification, and YAP/TAZ dysregulation. 🥼 💡AACR 2025 explores solutions ARTICLE: https://t.co/a9SfvOGyOS YouTube: https://t.co/ytBenpdIzw https://t.co/U32fLVw77J

  • Mashup Score: 10
    92% RFS at 2 Years: PD-1 Immunotherapy for MMRd / MSI-H Tumors at AACR 2025 - 20 day(s) ago

    Discover the impact of PD-1 immunotherapy on MMRd/MSI-H tumors. Learn about breakthrough results from AACR 2025.

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      🌟 Jaw-Dropper at AACR 2025! 🚀 Dr. Cercek unveils PD-1 immunotherapy results for MMRd/MSI-H tumors 🔸92% RFS at 2 years for 117 patients 🔸35% with no side effects 🔸Surgery avoided for many! See our companion video overview! 🔸🩺🎬👇 ARTICLE: https://t.co/tnCXm06Jh3 https://t.co/DXLlP6uTFC

  • Mashup Score: 46
    Antibody-Drug Conjugates: 40 Years of Cancer Treatment Innovation - 21 day(s) ago

    Explore the transformative potential of Antibody-Drug Conjugates in targeted cancer treatments and their impact on precision medicine.

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      📺Great companion video for "The Journey of Antibody–Drug Conjugates: 40 Years of Development" Dive deeper into groundbreaking ADC insights with #AACR25 @VriesElisabeth @raffcolo @AACRPres @PTarantinoMD OncologyTube: https://t.co/dT0wkA9Txa YouTube: https://t.co/VOeBlCeL28 https://t.co/URnDTf97eQ

  • Mashup Score: 11
    Zongertinib 71% ORR for HER2-Mutant NSCLC: Key Insights from AACR 2025 - 22 day(s) ago

    Explore the impact of Zongertinib HER2-Mutant NSCLC treatment with a 71% response rate in the latest Beamion LUNG-1 trial.

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      🚨HER2-Mutant NSCLC Update! 🔬Zongertinib (BI 1810631) shows promise: 🌟71% ORR 📅 12.4 mo PFS 🧠 Active in brain metastases (41% intracranial ORR) 📷 No ILD observed Comparison with trastuzumab deruxtecan + Clinical video snapshot below... ARTICLE: https://t.co/wHa778n2Hj https://t.co/q87eClz2L4

  • Mashup Score: 24
    Pembrolizumab KEYNOTE-689 Phase 3 Trial Update for LA-HNSCC at AACR 2025 - 24 day(s) ago

    Get the latest updates from the KEYNOTE-689 study on pembrolizumab and its impact on head and neck squamous cell carcinoma.

    Source: oncologytube.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      🔑KEYNOTE-689 Update at #AACR25 new standard? 🌟Neoadjuvant + adjuvant #pembrolizumab in LA-HNSCC 🌟 EFS HR: 0.73 (95% CI 0.58–0.92) 🌟2-yr EFS: 75% vs 62% 🌟CPS ≥10: HR 0.66 (95% CI 0.49–0.88) ❎OS pending—new standard? ARTICLE: https://t.co/dI5HxcolNY YouTube: https://t.co/iU4SXzTP3c

Load More